The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
=== Vitrification === Vitrification is a flash-freezing (ultra-rapid cooling) process that helps to prevent the formation of ice crystals and helps prevent cryopreservation damage. Researchers Greg Fahy and William F. Rall helped to introduce vitrification to reproductive cryopreservation in the mid-1980s. As of 2000, researchers claim vitrification provides the benefits of cryopreservation without damage due to ice crystal formation. The situation became more complex with the development of tissue engineering as both cells and biomaterials need to remain ice-free to preserve high cell viability and functions, integrity of constructs and structure of biomaterials. Vitrification of tissue engineered constructs was first reported by Lilia Kuleshova, who also was the first scientist to achieve vitrification of oocytes, which resulted in live birth in 1999. For clinical cryopreservation, vitrification usually requires the addition of cryoprotectants before cooling. Cryoprotectants are macromolecules added to the freezing medium to protect cells from the detrimental effects of intracellular ice crystal formation or from the solution effects, during the process of freezing and thawing. They permit a higher degree of cell survival during freezing, to lower the freezing point, to protect cell membrane from freeze-related injury. Cryoprotectants have high solubility, low toxicity at high concentrations, low molecular weight and the ability to interact with water via hydrogen bonding. Instead of crystallizing, the syrupy solution becomes an amorphous ice—it vitrifies.
Ayahuasca is a South American psychoactive decoction prepared from Banisteriopsis caapi vine and a dimethyltryptamine (DMT)-containing plant, used by Indigenous cultures in the Amazon and Orinoco basins as part of traditional medicine and shamanism. The word ayahuasca, originating from Quechuan languages spoken in the Andes, refers both to the B. caapi vine and the psychoactive brew made from it, with its name meaning 'spirit rope' or 'liana of the soul'. Although often portrayed as ancient, ayahuasca likely spread across the western Amazon only within the past few centuries; the first clear written accounts appear in the 17th century. The specific ritual use of ayahuasca was widespread among Indigenous groups by the 19th century. Ayahuasca is traditionally prepared by macerating and boiling B. caapi with other plants like Psychotria viridis during a ritualistic, multi-day process. Ayahuasca has been used in diverse South American cultures for spiritual, social, and medicinal purposes, often guided by shamans in ceremonial contexts involving specific dietary and ritual practices, with the Shipibo-Konibo people playing a significant historical and cultural role in its use. Originally confined to regions of Peru, Brazil, Colombia, and Ecuador, ayahuasca became widespread in Brazil, expanding widely by the mid-20th century through syncretic religions in Brazil.
== Working == A basic TDLAS setup consists of a tunable diode laser light source, transmitting (i.e. beam shaping) optics, optically accessible absorbing medium, receiving optics and detector/s. The emission wavelength of the tunable diode laser, viz. VCSEL, DFB, etc., is tuned over the characteristic absorption lines of a species in the gas in the path of the laser beam. This causes a reduction of the measured signal intensity due to absorption, which can be detected by a photodiode, and then used to determine the gas concentration and other properties as described later. Different diode lasers are used based on the application and the range over which tuning is to be performed. Typical examples are InGaAsP/InP (tunable over 900 nm to 1.6 μm), InGaAsP/InAsP (tunable over 1.6 μm to 2.2 μm), etc. These lasers can be tuned by either adjusting their temperature or by changing injection current density into the gain medium. While temperature changes allow tuning over 100 cm−1, it is limited by slow tuning rates (a few hertz), due to the thermal inertia of the system. On the other hand, adjusting the injection current can provide tuning at rates as high as ~10 GHz, but it is restricted to a smaller range (about 1 to 2 cm−1) over which the tuning can be performed. The typical laser linewidth is of the order of 10−3 cm−1 or smaller. Additional tuning, and linewidth narrowing, methods include the use of extracavity dispersive optics.
Sources: en.wikipedia.org
== Early life and education == Delibegovic is from Tuzla in Bosnia and Herzegovina. She grew up during the Bosnian War, which forced her family apart. In the early nineties, she moved to Scotland and finished her secondary school education at George Heriot's School in Edinburgh. Delibegovic studied pharmacology at the University of Edinburgh. In the final year of her undergraduate degree Delibegovic moved to Essex, where she did her undergraduate final year project at GlaxoSmithKline on novel anti-diabetes drugs. She completed her doctoral research with Prof Dame Patricia Cohen at the University of Dundee Medical Research Council Protein Phosphorylation Unit. Here she studied the way that enzymes such as protein phosphatase 1 influenced diabetes development. She was supported by the Royal Society studentship. She has said that she was interested in diabetes because of family history and prevalence of Type 2 diabetes in Bosnia and Herzegovina. During her doctoral research, Delibegovic worked closely with pharmaceutical companies to translate her research to the read world. In 2003 she was awarded the American Heart Association personal fellowship to study the role of PTPN1 in glucose homeostasis at the Harvard Medical School in Boston, USA. She spent four years in Boston, working with Prof Benjamin Neel on mouse models of insulin resistance.
There are biocompatible microalgae hybrid microrobots for active drug-delivery in the lungs and the gastrointestinal tract. The microrobots proved effective in tests with mice. In the two studies, "Fluorescent dye or cell membrane–coated nanoparticle functionalized algae motors were further embedded inside a pH-sensitive capsule" and "antibiotic-loaded neutrophil membrane-coated polymeric nanoparticles [were attached] to natural microalgae".
== Laboratory use == Levamisole reversibly and uncompetitively inhibits most isoforms of alkaline phosphatase (e.g., human liver, bone, kidney, and spleen) except the intestinal and placental isoform. It is thus used as an inhibitor along with substrate to reduce background alkaline phosphatase activity in biomedical assays involving detection signal amplification by intestinal alkaline phosphatase, for example in in situ hybridization or Western blot protocols. It is used to immobilize the nematode C. elegans on glass slides for imaging and dissection. In a C. elegans behavioral assay, analyzing the time course of paralysis provides information about the neuromuscular junction. Levamisole acts as an acetylcholine receptor agonist, which leads to muscle contraction. Continuing activation leads to paralysis. The time course of paralysis provides information about the acetylcholine receptors on the muscle. For example, mutants with fewer acetylcholine receptors may paralyze slower than wild type.
Sources: en.wikipedia.org
==== Demyelination ==== By the time chronic nerve compression becomes symptomatic, myelin tissue in the area of compression is likely damaged triggering a process called demyelination. This only affects the myelin sheath on myelinated axon while the axon and nerve continuity will remain preserved. Loss of myelin is often readily seen in histological samples as the layer of myelin around myelinated nerves will appear very thin, representing either the late stages of demyelination or early stages of remyelination. The pathology of fascicle to fascicle can vary. For example in some studies the central fascicles have appeared normal, while the peripheral fascicles showed significant thinning of myelin. Even within a fascicle, demyelination does not affect nerves uniformly. For example, in the early stages, demyelination can be seen at the edge of fascicles near the periphery of the nerve, and in later stages the demyelination is diffusely seen within the entirety of a fasicle. Damage to the myelin sheath of nerves is a nerve injury. It's classified as neuropraxia or a type 1 nerve injury using the Sunderland classification. It can cause a local conduction block for weeks to months as the myelin sheaths regrow, assuming no reinjury which would prolong recovery.
== Mode of action == It is believed that ω-grammotoxin SIA inhibits channel function by binding with high affinity to closed, resting states of the channel and that bound toxin makes it more difficult for channels to be opened by depolarization, so much larger depolarizations are required for channel activation.
6 November A PAVN sapper attack on Firebase St. George occupied by the 1st Battalion, 14th Infantry and 1st Battalion, 9th Artillery resulted in nine U.S. killed. MACV announced that it was holding back on sending U.S. ground forces to reinforce Duc Lap Camp as a test of the ARVN's abilities to handle higher intensity combat. The House Foreign Affairs Committee approved a resolution supporting Nixon's Vietnam policy.
== Books, documentaries, and miniseries == John Carreyrou, a Wall Street Journal journalist whose work exposed Theranos, published a book-length treatment in May 2018 titled Bad Blood: Secrets and Lies in a Silicon Valley Startup. A film version was reportedly scheduled for release in 2020, starring Jennifer Lawrence as Holmes, written by Vanessa Taylor and directed by Adam McKay. In January 2022, McKay stated that preparations for the film had resumed, and that Lawrence was working on learning Holmes's speech pattern. However, in November 2022, Lawrence announced she would no longer be involved with the project. In January 2019, ABC News Nightline released a podcast and documentary about the Holmes/Theranos story called The Dropout. A biographical miniseries with the same name, based on the eponymous podcast, premiered on Hulu in the US, Star+ in Latin America and Disney+ internationally in March 2022, with Amanda Seyfried as Holmes. Also in January 2019, a documentary film entitled The Inventor: Out for Blood in Silicon Valley about Holmes and Theranos was released. Directed by Alex Gibney, it made its debut at the Sundance Film Festival and was released March 2019 on HBO platforms. You Can See Everything, a documentary in which Elizabeth Holmes and partner Billy Evans invited filmmaker Nathan Fielder and co-director Lance Oppenheim to spend time with them, will be released on October 16, 2026.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.